Spyre Therapeutics Inc (NASDAQ: SYRE) on Tuesday, plunged -6.17% from the previous trading day, before settling in for the closing price of $28.67. Within the past 52 weeks, SYRE’s price has moved between $8.75 and $47.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -49.91% over the last five years. The company achieved an average annual earnings per share of 90.97%. With a float of $42.65 million, this company’s outstanding shares have now reached $51.43 million.
The firm has a total of 30 workers. Let’s measure their productivity. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Spyre Therapeutics Inc is 17.07%, while institutional ownership is 93.58%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -4.05 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.83) by -3.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.97% per share during the next fiscal year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Spyre Therapeutics Inc (SYRE) is currently performing well based on its current performance indicators. A quick ratio of 7.32 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -1.05 in the next quarter and is forecasted to reach -4.23 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Analysing the last 5-days average volume posted by the [Spyre Therapeutics Inc, SYRE], we can find that recorded value of 1.0 million was better than the volume posted last year of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 3.57%. Additionally, its Average True Range was 2.46.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 22.62%, which indicates a significant increase from 7.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.07% in the past 14 days, which was higher than the 62.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.31, while its 200-day Moving Average is $31.25. Now, the first resistance to watch is $27.89. This is followed by the second major resistance level at $28.87. The third major resistance level sits at $29.95. If the price goes on to break the first support level at $25.83, it is likely to go to the next support level at $24.75. Should the price break the second support level, the third support level stands at $23.77.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
Market capitalization of the company is 1.38 billion based on 51,431K outstanding shares. Right now, sales total 890 K and income totals -338,790 K. The company made 0 K in profit during its latest quarter, and -69,030 K in sales during its previous quarter.
